Get the Stockscreener App
11.48
8.30%
0.88
After Hours:
11.50
0.02
+0.17%
Neogenomics Inc stock is traded at $11.48, with a volume of 2.58M.
It is up +8.30% in the last 24 hours and up +10.07% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$10.60
Open:
$10.6
24h Volume:
2.58M
Relative Volume:
0.75
Market Cap:
$1.49B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-18.52
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+11.03%
1M Performance:
+10.07%
6M Performance:
+55.14%
1Y Performance:
-25.41%
1-Day Range:
$10.36
$11.52
1-Week Range:
$9.89
$11.52
52-Week Range:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
11.48 | 1.37B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
587.48 | 215.18B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.39 | 156.94B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
725.91 | 55.05B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
151.25 | 41.12B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
224.90 | 36.97B | 15.90B | 1.28B | 2.21B | 7.2842 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know - Yahoo Finance
First Week of January 2026 Options Trading For NeoGenomics (NEO) - Nasdaq
How NeoGenomics Inc. stock compares to market leadersWeekly Trade Review & Weekly Top Gainers Trade List - newser.com
Can NeoGenomics Inc. (NG9) stock sustain revenue momentumJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
How hedge fund analytics apply to NeoGenomics Inc. stock2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Is NeoGenomics Inc. stock a buy on dipsLayoff News & Smart Swing Trading Techniques - newser.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in NeoGenomics, Inc. $NEO - MarketBeat
Is NeoGenomics Inc. (NG9) stock cheap by valuation metricsDividend Hike & Proven Capital Preservation Tips - newser.com
Earnings visualization tools for NeoGenomics Inc.2025 Earnings Impact & High Conviction Trade Alerts - newser.com
Is NeoGenomics Inc. (NG9) stock attractive for growth fundsMarket Activity Report & Daily Profit Focused Stock Screening - newser.com
Will NeoGenomics Inc. (NG9) stock beat value stocksJuly 2025 Snapshot & Smart Allocation Stock Tips - newser.com
Will earnings trigger a reversal in NeoGenomics Inc.Buy Signal & Safe Capital Growth Plans - newser.com
Will NeoGenomics Inc. (NG9) stock beat Nasdaq index returns2025 Historical Comparison & Precise Swing Trade Entry Alerts - newser.com
NeoGenomics at Stephens Conference: Strategic Growth Amid Pharma Challenges By Investing.com - Investing.com Canada
Will NeoGenomics Inc. stock maintain dividend yieldTrade Risk Report & Growth Oriented Trade Recommendations - newser.com
Price momentum metrics for NeoGenomics Inc. explainedJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Will NeoGenomics Inc. (NG9) stock announce a stock split2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Developing predictive dashboards with NeoGenomics Inc. dataMarket Risk Analysis & Long-Term Safe Investment Ideas - newser.com
Sector ETF performance correlation with NeoGenomics Inc.IPO Watch & Weekly Market Pulse Alerts - newser.com
How risky is NeoGenomics Inc. stock nowMarket Performance Summary & Verified Momentum Stock Alerts - newser.com
Avoiding Lag: Real-Time Signals in (NEO) Movement - news.stocktradersdaily.com
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):